Analysts Set Vera Therapeutics, Inc. (NASDAQ:VERA) Target Price at $74.83

Vera Therapeutics, Inc. (NASDAQ:VERA) has been given a consensus recommendation of “Moderate Buy” by the twelve research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and nine have given a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $74.8333.

Several equities analysts recently weighed in on the stock. TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a research note on Friday, December 5th. Pivotal Research set a $73.00 price objective on shares of Vera Therapeutics in a report on Friday, December 5th. Wedbush raised their price objective on Vera Therapeutics from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a report on Wednesday, January 21st. Finally, Evercore ISI increased their price target on Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a research note on Monday, December 8th.

Vera Therapeutics Stock Up 4.7%

NASDAQ VERA opened at $45.28 on Friday. Vera Therapeutics has a 12 month low of $18.53 and a 12 month high of $56.05. The company has a current ratio of 12.21, a quick ratio of 12.21 and a debt-to-equity ratio of 0.19. The stock has a market cap of $2.89 billion, a PE ratio of -11.35 and a beta of 1.16. The stock’s 50 day moving average is $46.20 and its 200 day moving average is $32.82.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.06). During the same quarter last year, the firm earned ($0.85) EPS. Research analysts predict that Vera Therapeutics will post -2.89 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Patrick G. Enright bought 5,882 shares of the stock in a transaction dated Thursday, December 11th. The stock was purchased at an average cost of $42.50 per share, for a total transaction of $249,985.00. Following the transaction, the director owned 5,882 shares of the company’s stock, valued at $249,985. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Joseph R. Young sold 15,000 shares of the business’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $29.06, for a total transaction of $435,900.00. Following the completion of the sale, the senior vice president owned 47,839 shares in the company, valued at $1,390,201.34. This represents a 23.87% decrease in their position. The disclosure for this sale is available in the SEC filing. 16.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Vera Therapeutics

Hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Vera Therapeutics by 7.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock worth $753,000 after acquiring an additional 2,210 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Vera Therapeutics by 22.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock valued at $2,354,000 after purchasing an additional 17,907 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Vera Therapeutics by 297.1% in the 1st quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock worth $999,000 after purchasing an additional 62,678 shares during the period. J. Safra Sarasin Holding AG bought a new position in shares of Vera Therapeutics during the 2nd quarter valued at approximately $697,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Vera Therapeutics during the 2nd quarter valued at $237,000. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.